IBC Life Sciences announced recently the finalists for the third annual Pharmaceutical Achievement Awards.
Among them are RNAi pioneers Craig Mello, of the University of Massachusetts Medical School, and Phillip Sharp, of the Massachusetts Institute of Technology, both of whom have been nominated for the academic scientist of the year award.
The awards are to be presented on Aug. 8 at the Boston Harbor Hotel in Boston, Mass.
Nucleonics has named James Barrett, general partner at New Enterprise Associates, as chairman of its board. The company also said that Giovanni Ferrara, a director at Burrill & Co., has joined the board.
Both NEA and Burrill are major Nucleonics shareholders.
Barrett assumes his new role following the departure of Elaine Jones, according to Nucleonics.
He sits on the boards of such companies as Eximias Pharmaceutical, GlycoMimetics, Inhibitex, Iomai, Peptimmune, Pharmion, Sensors for Medicine and Science, and Targacept. He is also a director of MedImmune, said NEA.
Barrett received a PhD in biochemistry from the University of Tennessee, an MBA from the University of Santa Clara, and a BS in chemistry from Boston College, according to NEA.
Ferrara currently sits on the boards of Agilix, Spectral Genomics, and MetriGenix, according to Burrill.
Prior to joining Burrill, Ferrara was a manager at venture capital firm GeneChem Management. Before this, he served as a financial analyst at Letko, Brosseau & Associates.
He holds an MBA and a BS in physiology from McGill University.